A phase III trial of Toca 511 + Toca FC in patients with newly diagnosed HGG and other solid tumors:Toca 5

Trial Profile

A phase III trial of Toca 511 + Toca FC in patients with newly diagnosed HGG and other solid tumors:Toca 5

Planning
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Vocimagene amiretrorepvec-flucytosine gene therapy (Primary)
  • Indications Glioma; Solid tumours
  • Focus Registrational; Therapeutic Use
  • Sponsors Tocagen
  • Most Recent Events

    • 08 Nov 2017 According to a Tocagen media release, the company has modified two-step trial design (Phase 2 followed by a Phase 3) into this seamless, pivotal trial.
    • 11 Mar 2016 New trial record
    • 08 Mar 2016 This trial is expected to begin in 2016, according to a Tocagen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top